TY - JOUR
T1 - Oral Immunotherapy–Related Awareness, Attitudes, and Experiences Among a Nationally Representative Sample of Food Allergy Patients/Caregivers
AU - Warren, Christopher M.
AU - Roach, Anita
AU - Das, Rajeshree
AU - Casale, Thomas B.
AU - Vickery, Brian P.
AU - Wasserman, Richard L.
AU - Gupta, Ruchi S.
N1 - Funding Information:
Conflicts of interest: C. M. Warren reports research support from the National Institute of Allergy and Infectious Disease; the Sunshine Foundation; Food Allergy Research and Educadtion and has served as an epidemiological consultant for Alladapt Immunotherapeutics. A. Roach is Vice President of Community Access and Education at FARE. T. B. Casale served as an investigator on Aimmune clinical trials and currently serves as Distinguished Chairman of the FARE Clinical Network. B. P. Vickery reports research grants from NIH-NIAID and Food Allergy Research and Education (FARE) as well as other research support from Aimmune Therapeutics ; DBV Technologies ; Genentech ; and Regeneron via clinical research contracts to his institution; has also has served in a consultant/advisory capacity for Aimmune Therapeutics; AllerGenis, LLC; FARE; Reacta Biosciences; and Regeneron. R. S. Gupta receives research grant support from the National Institutes of Health (NIH), Food Allergy Research and Education (FARE), Stanford Sean N. Parker Center for Allergy Research, UnitedHealth Group, Thermo Fisher Scientific, Genentech, and the National Confectioners Association (NCA); and has served as a medical consultant/advisor for Aimmune Therapeutics, Genentech, Before Brands, Kaléo, DBV Technologies, ICER, DOTS Technology, and FARE. The rest of the authors declare that they have no relevant conflicts of interest.
Publisher Copyright:
© 2021
PY - 2021/11
Y1 - 2021/11
N2 - Background: Advances in oral immunotherapy (OIT) have led to recently expanded treatment options for food allergy (FA) patients. However, to inform future outreach efforts and ensure equitable access to emerging treatments, a greater understanding of current OIT-related awareness, attitudes, and experiences is needed. Objective: To characterize current OIT awareness, attitudes, and experiences among a nationally representative sample of U.S. adults with FA and parents/caregivers of pediatric patients. Methods: A probability-based sample of U.S. adults and parents/caregivers of children with FA was surveyed about OIT-related knowledge, attitudes, and experiences. Results: Surveys were completed by respondents (n = 781) from all 50 states. Overall, 72% did not know what OIT was prior to the survey. Respondents from households earning over $100,000 or with a college degree each had significantly greater odds of reporting any OIT awareness compared with lower-income (odds ratio 2.0; 95% confidence interval 1.2-3.4) and non–college-educated (odds ratio 1.9; 95% confidence interval 1.2-3.0) respondents. Among respondents familiar or unfamiliar with OIT, 54% and 34%, respectively, reported their expected treatment outcome was to obtain protection against accidental exposure. Among respondents familiar or unfamiliar with OIT, 38% and 35%, respectively, reported their expected treatment outcome to be curing the allergy. Furthermore, 55% of OIT unfamiliar respondents said they would not be comfortable initiating a conversation with their health care provider about their suitability for OIT. Conclusions: This study shows that, among a nationally representative sample of FA patients and pediatric caregivers, awareness of OIT is low, and over 95% of patients lack personal experience with OIT. Furthermore, the data suggest current OIT awareness is disproportionately elevated among wealthier, more highly educated respondents.
AB - Background: Advances in oral immunotherapy (OIT) have led to recently expanded treatment options for food allergy (FA) patients. However, to inform future outreach efforts and ensure equitable access to emerging treatments, a greater understanding of current OIT-related awareness, attitudes, and experiences is needed. Objective: To characterize current OIT awareness, attitudes, and experiences among a nationally representative sample of U.S. adults with FA and parents/caregivers of pediatric patients. Methods: A probability-based sample of U.S. adults and parents/caregivers of children with FA was surveyed about OIT-related knowledge, attitudes, and experiences. Results: Surveys were completed by respondents (n = 781) from all 50 states. Overall, 72% did not know what OIT was prior to the survey. Respondents from households earning over $100,000 or with a college degree each had significantly greater odds of reporting any OIT awareness compared with lower-income (odds ratio 2.0; 95% confidence interval 1.2-3.4) and non–college-educated (odds ratio 1.9; 95% confidence interval 1.2-3.0) respondents. Among respondents familiar or unfamiliar with OIT, 54% and 34%, respectively, reported their expected treatment outcome was to obtain protection against accidental exposure. Among respondents familiar or unfamiliar with OIT, 38% and 35%, respectively, reported their expected treatment outcome to be curing the allergy. Furthermore, 55% of OIT unfamiliar respondents said they would not be comfortable initiating a conversation with their health care provider about their suitability for OIT. Conclusions: This study shows that, among a nationally representative sample of FA patients and pediatric caregivers, awareness of OIT is low, and over 95% of patients lack personal experience with OIT. Furthermore, the data suggest current OIT awareness is disproportionately elevated among wealthier, more highly educated respondents.
KW - Food allergy
KW - Food allergy treatment
KW - Oral immunotherapy
UR - http://www.scopus.com/inward/record.url?scp=85114668725&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85114668725&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2021.07.020
DO - 10.1016/j.jaip.2021.07.020
M3 - Article
C2 - 34333192
AN - SCOPUS:85114668725
SN - 2213-2198
VL - 9
SP - 4087-4094.e3
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 11
ER -